CSOP Bitcoin Futures Daily (-1x) Inverse Product
07376
Harvest Bitcoin Spot ETF
03439
ChinaAMC Bitcoin ETF
03042
CSOP Bitcoin Futures ETF
03066
Samsung Bitcoin Futures Active ETF
03135
HK Stock MarketDetailed Quotes
02196 FOSUN PHARMA
- 14.300
- -0.260-1.79%
Not Open Dec 13 16:08 CST
38.10BMarket Cap16.16P/E (TTM)
14.560High14.300Low2.85MVolume14.560Open14.560Pre Close40.89MTurnover0.52%Turnover Ratio14.40P/E (Static)2.66BShares19.50052wk High0.73P/B7.80BFloat Cap11.02052wk Low0.30Dividend TTM545.12MShs Float80.580Historical High0.301Dividend LFY1.79%Amplitude5.897Historical Low14.363Avg Price500Lot Size2.10%Div YieldTTM2.10%Div Yield LFY
FOSUN PHARMA Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0.69%30.91B | -4.38%20.38B | -6.56%10.16B | -5.85%41.25B | -2.92%30.7B | 0.16%21.32B | 4.71%10.87B | 12.73%43.81B | 16.91%31.62B | 26.10%21.28B |
| Operating income | 0.69%30.91B | -4.38%20.38B | -6.56%10.16B | -5.85%41.25B | -2.92%30.7B | 0.16%21.32B | 4.71%10.87B | 12.73%43.81B | 16.91%31.62B | 26.10%21.28B |
| Cost of sales | ---- | 2.20%-10.46B | ---- | 6.80%-21.6B | ---- | 7.60%-10.7B | ---- | -14.53%-23.17B | ---- | -40.23%-11.58B |
| Operating expenses | -0.70%-15.89B | 2.20%-10.46B | 4.10%-5.08B | 6.80%-21.6B | 6.70%-15.78B | 7.60%-10.7B | 9.66%-5.29B | -14.53%-23.17B | -24.03%-16.91B | -40.23%-11.58B |
| Gross profit | 0.68%15.02B | -6.57%9.92B | -8.90%5.08B | -4.79%19.65B | 1.43%14.92B | 9.41%10.62B | 23.34%5.58B | 10.77%20.64B | 9.68%14.71B | 12.56%9.7B |
| Selling expenses | 8.78%-6.59B | 15.87%-4.27B | 10.93%-2.24B | -5.90%-9.71B | -11.23%-7.23B | -21.46%-5.07B | -21.70%-2.52B | -0.77%-9.17B | 0.94%-6.5B | 0.86%-4.18B |
| Administrative expenses | 0.77%-3.14B | -2.17%-2.15B | -1.13%-1B | -14.80%-4.5B | -20.61%-3.17B | -22.11%-2.1B | -26.17%-991.09M | -18.15%-3.92B | -16.73%-2.63B | -14.44%-1.72B |
| Research and development expenses | 16.07%-2.65B | 12.77%-1.86B | 14.38%-829.57M | -1.02%-4.35B | -10.22%-3.16B | -16.81%-2.13B | -20.31%-968.87M | -12.11%-4.3B | -18.60%-2.86B | -16.98%-1.83B |
| Profit from asset sales | -60.10%2.51M | ---- | 185.51%434.1K | ---- | -95.50%6.3M | ---- | -173.65%-507.68K | ---- | 2,026.44%140.1M | ---- |
| Revaluation surplus | -113.18%-106.25M | ---- | 86.36%-20.14M | ---- | 141.76%806.34M | ---- | 89.13%-147.61M | ---- | -245.96%-1.93B | ---- |
| -Changes in the fair value of other assets | -113.18%-106.25M | ---- | 86.36%-20.14M | ---- | 141.76%806.34M | ---- | 89.13%-147.61M | ---- | -245.96%-1.93B | ---- |
| Impairment and provision | 74.38%-95.41M | 34.39%-38.04M | 58.87%-10.53M | -101.82%-131.93M | -189.88%-372.49M | -153.61%-57.98M | -328.87%-25.6M | 11.68%-65.37M | 51.81%-128.49M | -54.42%-22.86M |
| -Other impairment is provision | 74.38%-95.41M | 34.39%-38.04M | 58.87%-10.53M | -101.82%-131.93M | -189.88%-372.49M | -153.61%-57.98M | -328.87%-25.6M | 11.68%-65.37M | 51.81%-128.49M | -54.42%-22.86M |
| Operating interest expense | ---- | -17.60%-709.55M | ---- | ---- | ---- | -37.47%-603.38M | ---- | ---- | ---- | ---438.91M |
| Special items of operating profit | -29.30%1.76B | -80.38%194.7M | -49.69%416.77M | 353.64%1.09B | -24.67%2.49B | 2,266.92%992.21M | -46.80%828.41M | -91.36%239.26M | 62.78%3.3B | -97.11%41.92M |
| Operating profit | -3.32%3.96B | -33.52%1.09B | -22.91%1.3B | -40.08%2.05B | 4.02%4.1B | 5.12%1.64B | 68.38%1.69B | -19.44%3.43B | -22.64%3.94B | -43.83%1.56B |
| Financing income | ---- | ---- | ---- | 28.66%363.65M | ---- | ---- | ---- | --282.64M | ---- | ---- |
| Financing cost | -13.03%-854.56M | ---- | -7.26%-280.22M | -37.46%-1.32B | -99.46%-756.08M | ---- | -144.62%-261.26M | ---963.81M | 3.66%-379.07M | ---- |
| Share of profits of associates | ---- | -15.29%947.2M | ---- | 15.36%2.39B | ---- | 24.43%1.12B | ---- | 1.60%2.07B | ---- | -2.92%898.58M |
| Share of profit from joint venture company | ---- | -10.47%-105.88M | ---- | 13.63%-202.03M | ---- | 3.74%-95.84M | ---- | 5.44%-233.93M | ---- | -6.13%-99.56M |
| Special items of earning before tax | 27.58%-36.02M | ---- | 93.06%-2.94M | ---- | 73.78%-49.74M | ---- | -410.57%-42.38M | ---- | -474.73%-189.71M | ---- |
| Earning before tax | -6.71%3.07B | -27.44%1.93B | -26.46%1.02B | -28.46%3.28B | -2.33%3.29B | 12.85%2.66B | 56.00%1.38B | -24.20%4.58B | -27.76%3.37B | -28.62%2.36B |
| Tax | 13.40%-553.05M | 37.49%-381.47M | 14.16%-232.2M | 41.06%-369.5M | -4.43%-638.65M | -19.87%-610.25M | -11.16%-270.51M | 41.21%-626.92M | 16.37%-611.54M | 7.55%-509.09M |
| After-tax profit from continuing operations | -5.10%2.52B | -24.45%1.55B | -29.44%786.22M | -26.46%2.91B | -3.83%2.65B | 10.92%2.05B | 72.94%1.11B | -20.55%3.95B | -29.87%2.76B | -32.84%1.85B |
| Earning after tax | -5.10%2.52B | -24.45%1.55B | -29.44%786.22M | -26.46%2.91B | -3.83%2.65B | 10.92%2.05B | 72.94%1.11B | -20.55%3.95B | -29.87%2.76B | -32.84%1.85B |
| Minority profit | 36.99%507.88M | 21.36%324.93M | 38.66%176.49M | 134.84%508.8M | 14.66%370.74M | -12.93%267.75M | -29.98%127.28M | -12.48%216.66M | -12.66%323.34M | 13.38%307.51M |
| Profit attributable to shareholders | -11.93%2.01B | -31.33%1.22B | -38.22%609.73M | -35.81%2.4B | -6.29%2.28B | 15.68%1.78B | 113.39%986.97M | -20.97%3.74B | -31.66%2.44B | -37.89%1.54B |
| Basic earnings per share | -12.79%0.75 | -31.34%0.46 | -37.84%0.23 | -37.06%0.9 | -8.51%0.86 | 11.67%0.67 | 105.56%0.37 | -22.70%1.43 | -32.37%0.94 | -38.14%0.6 |
| Diluted earnings per share | -11.76%0.75 | -31.34%0.46 | -37.84%0.23 | -37.06%0.9 | -9.57%0.85 | 11.67%0.67 | 105.56%0.37 | -22.70%1.43 | -32.37%0.94 | -38.14%0.6 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Trending HK Stocks
HK Crypto ETF HK Crypto ETF
An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data. An exchange-traded fund designed to track the price performance of Bitcoin or other major crypto, allowing investors to participate in the market without directly purchasing the assets.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK Crypto ETF, ranked from highest to lowest based on real-time market data.
